IL17A and colitis: The in vivo results revealed that acute oral administration of GO increased the extent of colitis, accompanied by the release of pro-inflammatory cytokines (IL-6, IL-17, and IFN-γ) and apparent apoptosis in the intestinal mucosal epithelium.